The Promise of a Wnt Agonist

Show Description +

Dr. Wykoff discusses 12-week results from the AMARONE phase 1b/2a trial of restoret (EYE103, EyeBio) for the treatment of diabetic macular edema and wet AMD.

Posted: 10/28/2024

Keywords:

retina-meeting-recap

•

Clinical Trials

•

EyeBio

•

EYE103

•

restoret

•

Diabetic macular edema, DME

•

Age-Related Macular Degeneration (AMD)

Up Next

Name: The Promise of a Wnt Agonist
Uploaded: 2024-10-28T18:40:55+00:00
Description: Dr. Wykoff discusses 12-week results from the AMARONE phase 1b/2a trial of restoret (EYE103, EyeBio) for the treatment of diabetic macular edema and wet AMD.

Visual Function with Mac-Tel Type 2 Treatment

Roger A. Goldberg, MD, MBA

The Risk of PVR Revealed

Mathew W. MacCumber, MD, PHD

A Novel Scleral Buckling Technique

Maria H. Berrocal, MD

The Challenges of Epiretinal Membrane Surgery

Yasha S. Modi, MD

The 2024 Charles L Schepens MD Lecture

Steve Charles, MD, FACS, FICS

Fellow-Eye Dosing of ABBV-RGX-314 Gene Therapy

Arshad M. Khanani, MD, MA, FASRS

Managing Elderly Patients With Advanced, Progressive Disease

Jody Piltz-Seymour, MD

Home Testing Ready for Prime Time?

Rachel G. Simpson, MD

Association Between GLP-1 Receptor Agonists Exposure and IOP Change

Qi N. Cui, MD, PhD

Expanding Adjustable IOL Technology

Mitchell Weikert, MD

Presbyopia-Correcting IOLs: New Categories?

Daniel H. Chang, MD

$Lenticule Extraction and Corneal Refractive Surgery$

Lenticule Extraction and Corneal Refractive Surgery

Audrey Talley Rostov, MD

Genetic Testing for Primary Open-Angle Glaucoma

Anthony P. Khawaja, MBBS

Glaucoma Lasers: What’s New?

Sarah Van Tassel, MD

Visual Field Progression in the LiGHT Trial

Gus Gazzard, MA(Cantab), MD, MBBChir, FRCOphth

$Intense Pulsed Light Therapy and Refractive Surgery$

Intense Pulsed Light Therapy and Refractive Surgery

Jorge Alio Del Barrio, MD, PhD

$Frequency and Risk Factors for Ocular Pain After Refractive Surgery$

Frequency and Risk Factors for Ocular Pain After Refractive Surgery

Jason Betz, BS

Digital Imaging and Software Revolution in Ophthalmology

Cathleen McCabe, MD

Sequential CAIRS and Combined Wavefront-Guided PRK and CXL

Shady T. Awwad, MD

Causes and Prevention of TASS During Anterior Segment Surgery

Nick Mamalis, MD

Technology-Driven Tools for Improving Patient Care and Physician Wellness

Renee Bovelle, MD

36 Months of GA Therapy with Pegcetacoplan

Dilsher S. Dhoot, MD

A Look at Topline Data: EYP-1901

Carl D. Regillo, MD

Updates on a Novel Oral Therapy for DME

Joel A. Pearlman, MD, PhD

Extension Data for High-Dose Aflibercept

Diana Do, MD

Back to All Videos

The Promise of a Wnt Agonist

Charles C. Wykoff, MD, PhD

Dr. Wykoff discusses 12-week results from the AMARONE phase 1b/2a trial of restoret (EYE103, EyeBio) for the treatment of diabetic macular edema and wet AMD.

Posted: 10/28/2024

Keywords:

retina-meeting-recap

•

Clinical Trials

•

EyeBio

•

EYE103

•

restoret

•

Diabetic macular edema, DME

•

Age-Related Macular Degeneration (AMD)

Please log in to leave a comment.

Meeting Coverage:

American Academy of Ophthalmology

The Promise of a Wnt Agonist

Up Next

The Promise of a Wnt Agonist

More From AAO: 2024 Coverage